Patents by Inventor Laurent Ladaviere

Laurent Ladaviere has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antigenic structural peptide, antigenic and immunogenic compounds, and uses for detecting, preventing and treating an HCV infection
    Patent number: 6964852
    Abstract: The invention concerns a structural peptide, identified by antibodies directed against a polypeptide, comprising the 2-45 amino acid sequence of the N-terminal end of the Core or nucleocapsid (p21) protein of the hepatitis C virus (HCV), excluding any protein or peptide compound comprising or consisting of the N-terminal end. The invention is characterized in that it comprises a tertiary structure consisting of at least a first peptide fragment having a secondary structure in ? helix, a second peptide fragment having secondary structure in ? helix and a third peptide bond fragment linking the two ? helices, these two ? helices being substantially perpendicular to each other in space. This peptide can be used for detecting antibodies directed against the p21 protein of HCV, for detecting all of part of the RNA of HCV and for preparing a diagnostic, prophylactic or therapeutic composition for detecting, preventing or treating an HCV infection.
    Type: Grant
    Filed: February 19, 2003
    Date of Patent: November 15, 2005
    Assignee: Bio Merieux
    Inventors: Michel Jolivet, Francois Penin, Pascal Dalbon, Laurent Ladaviere, Xavier Lacoux
  • Antigenic structural peptide, antigenic and immunogenic compounds, and uses for detecting, preventing and treating an HCV infection
    Publication number: 20030118604
    Abstract: The invention concerns a structural peptide, identified by antibodies directed against a polypeptide, comprising the 2-45 amino acid sequence of the N-terminal end of the Core or nucleocapsid (p21) protein of the hepatitis C virus (HCV), excluding any protein or peptide compound comprising or consisting of the N-terminal end. The invention is characterized in that it comprises a tertiary structure consisting of at least a first peptide fragment having a secondary structure in &agr; helix, a second peptide fragment having secondary structure in &agr; helix and a third peptide bond fragment linking the two &agr; helices, these two &agr; helices being substantially perpendicular to each other in space. This peptide can be used for detecting antibodies directed against the p21 protein of HCV, for detecting all of part of the RNA of HCV and for preparing a diagnostic, prophylactic or therapeutic composition for detecting, preventing or treating an HCV infection.
    Type: Application
    Filed: February 19, 2003
    Publication date: June 26, 2003
    Applicant: Bio Merieux
    Inventors: Michel Jolivet, Francois Penin, Pascal Dalbon, Laurent Ladaviere, Xavier Lacoux
  • Antigenic structural peptide, antigenic and immunogenic compounds, and uses for detecting, preventing and treating an HCV infection
    Patent number: 6576240
    Abstract: The invention concerns a structural peptide, identified by antibodies directed against a polypeptide, comprising the 2-45 amino acid sequence of the N-terminal end of the Core or nucleocapsid (p21) protein of the hepatitis C virus (HCV), excluding any protein or peptide compound comprising or consisting of the N-terminal end. The invention is characterized in that it comprises a tertiary structure consisting of at least a first peptide fragment having a secondary structure in &agr; helix, a second peptide fragment having secondary structure in &agr; helix and a third peptide bond fragment linking the two &agr; helices, these two &agr; helices being substantially perpendicular to each other in space. This peptide can be used for detecting antibodies directed against the p21 protein of HCV, for detecting all of part of the RNA of HCV and for preparing a diagnostic, prophylactic or therapeutic composition for detecting, preventing or treating an HCV infection.
    Type: Grant
    Filed: September 7, 1999
    Date of Patent: June 10, 2003
    Assignee: Bio Merieux
    Inventors: Michel Jolivet, François Penin, Pascal Dalbon, Laurent Ladaviere, Xavier Lacoux